Distribution and anti-HBV effects of antisense oligodeoxynu-cleotides conjugated to galactosylated poly-L-lysine

Table 1 Inhibition of asODNs on HBsAg and HBeAg secretion in 2.2.15 cells (P/N values ^–x ± s)

Groups	HBsAg	Inhibitory rate (%)	HBeAg	Inhibitory rate (%)
Cell control	9.4 ± 0.16		15.10 ± 0.15
PS-asODNs	4.30 ± 0.25	70	7.60 ± 1.10	58
Gal-PLL:PS-asODNs	2.40 ± 0.26	96	4.50 ± 0.42	82
Gal-PLL:PS-ODNs	8.10 ± 0.13	19	13.80 ± 0.76	10

Table 2 Change of serum HBsAg (the value of OD) between pretreatment and posttreatment in HBV transgenic mice

Groups	Pieces (n)	Days of therapy
		Pretreatment	The 12th day
Normal saline	6	1.335 ± 0.769	1.262 ± 0.765a
Gal- PLL-asODNs	6	1.608 ± 0.658	0.733 ± 0.547b

Note: Matched t test analysis showed that, compared with pretreatment,

^aP > 0.05;

^bP < 0.01.